Is the superior efficacy of new generation antipsychotics an artifact of LOCF?

Schizophrenia Bulletin

Volumn 33, Issue 1, 2007, Pages 183-191

  Leucht, Stefan ^a   Engel, Rolf R ^b   Bäuml, Josef ^a   Davis, John M ^c,d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Amisulpride; Atypical antipsychotics; Bias; Olanzapine; Schizophrenia

Indexed keywords

AMISULPRIDE; FLUPENTIXOL; HALOPERIDOL; OLANZAPINE;

ADULT; AGITATION; AKATHISIA; ARTICLE; CALCULATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG WITHDRAWAL; EFFECT SIZE; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NONRESPONSE BIAS; PARKINSONISM; PATIENT CODING; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SENSITIVITY ANALYSIS; SIDE EFFECT; STANDARDIZATION; THEORETICAL MODEL; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; UNSPECIFIED SIDE EFFECT;

ARTIFACTS; BENZODIAZEPINES; BIAS (EPIDEMIOLOGY); FLUPENTHIXOL; HALOPERIDOL; HUMANS; PATIENT DROPOUTS; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTROPIC DRUGS; RANDOMIZED CONTROLLED TRIALS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SULPIRIDE; TREATMENT OUTCOME;

EID: 33845912693     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbl025     Document Type: Article

References (35)

1. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res. 1999;35:51-68.
2. Leucht S, Pitschel-Walz G, Engel R, Kissling W. Amisulpride - an unusual atypical antipsychotic. A meta-analysis of randomized controlled trials. Am J Psychiatry. 2002;159:180-190.
3. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry. 2003;60:553-564.
4. Rosenheck RA. Effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator. Psychiatr Serv. 2005;56:85-92.
5. Colonna L, Saleem P, Dondey-Nouvel L, Rein W. Amisulpride study group. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Int Clin Psychopharmacol. 2000;15:13-22.
6. Carrière P, Bonhomme D, Lempérière T. Amisulpride has superior benefit: risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride study group). Eur Psychiatry. 2000;15:321-329.
7. Möller HJ, Boyer P, Fleurot O, Rein W. Improvement of acute exacerbations of schizophrenia with amisulpride: a comparison with haloperidol. Psychopharmacology. 1997;132:396-401.
8. Puech A, Fleurot O, Rein W. Amisulpride, an atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs haloperidol. Acta Psychiatr Scand. 1998;98:65-72.
9. Wetzel H, Grunder G, Hillert A, et al. Amisulpride versus flupentixol in schizophrenia with predominantly positive symptomatology - a double-blind controlled study comparing a selective D-2-like antagonist to a mixed D-1-/D-2-like antagonist. Psychopharmacology. 1998;137:223-232.
10. Beasley CM, Tollefson GD, Tran P, et al. Olanzapine versus haloperidol and placebo. Acute phase results of the american double-blind olanzapine trial. Neuropsychopharmacology. 1996;14:111-123.
11. Beasley CM, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol. 1997;7:125-137.
12. Tollefson GD, Beasley CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry. 1997;154:457-465.
13. Speller JC, Barnes TRE, Curson DA, Pantelis C, Alberts JL. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms - amisulpride v. haloperidol. Br J Psychiatry. 1997;171:564-568.
14. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10:790-812.
15. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-275.
16. Klein HE, Dieterle D, Rüther E, Eben E, Nedopil N, Hippius H. A double-blind comparison of amisulpride vs haloperidol in acute schizophrenic patients. In: Pichot P, Berner P, Wolf R, Thau K, eds. Psychiatry, the State of the Art. Cambridge, Mass: Plenum Press; 1985:687-691.
17. Pichot P, Boyer P. Etude multicentrique controlée en double insu: amisulpride (Solian 200) versus halopéridol à forte dose dans les états psychotiques aigus. Ann Psychiatr. 1988;3(3):326-332.
18. Pichot P, Boyer P. Controlled double-blind multi-centre trial of low dose amisulpride versus fluphenazine in the treatment of the negative syndrome of chronic schizophrenia. Amisulpride. Paris, France: Expansion scientifique francaise; 1989:125-137.
19. Costa e Silva JA. Comparative double-blind study of amisulpride versus haloperidol in the treatment of acute psychotic states. Amisulpride. Paris, France: Expansion scientifique francaise; 1989:93-104.
20. Delcker A, Schoon ML, Oczkowski B, Gaertner HJ. Amisulpride versus haloperidol in treatment of schizophrenic patients - results of a double-blind study. Pharmacopsychiatry. 1990;23:125-130.
21. Ziegler B. Study of the efficacy of a substituted benzamide amisulpride, versus haloperidol, in productive schizophrenia. Amisulpride. Paris, France: Expansion scientifique francaise; 1989:73-81.
22. American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders. third revision, revised (DSM-III-R). Washington, DC: American Psychiatric Association; 1987.
23. American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 1994.
24. Adams CE, Coutinho E, Duggan L, Leucht S, Srisurapanont M, Tharyan P. Cochrane Schizophrenia Group. The Cochrane Library. Chichester, UK: John Wiley & Sons Ltd; 2005.
25. Rosenthal R. Meta-analytic Procedures for Social Research. 2nd ed. New York, NY: Sage Publications; 1991.
26. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ. 2000;321:1371-1376.
27. Kinon BJ, Liu-Seifert H, Adams DH. Predominance of psychiatric-based reasons for antipsychotic treatment discontinuation. Biol Psychiatry. 2005;57:105S-106S.
28. Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia - a randomized controlled trial. JAMA. 2003;290:2693-2702.
29. Lieberman JA, Phillips M, Gu H, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology. 2003;28:995-1003.
30. Lieberman JA, Tollefson G, Tohen M, et al. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry. 2003;160:1396-1404.
31. Emsley RA. Risperidone Working Group. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Schizophr Bull. 1999;25:721-729.
32. Heres S, Davis JM, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine and quetiapine beats olanzapine again. An exploratory analysis of head-to-head comparisons of second generation antipsychotics. Am J Psychiatry. 2006;163:180-194.
33. Mallinckrodt CH, Watkin JG, Molenberghs G, Carroll RJ. Choice of the primary analysis in longitudinal clinical trials. Pharma Stat. 2004;3(3):161-169.
34. Leon AC, Mallinckrodt CH, Chuang-Stein CC, Archibald DG, Archer GE, Chartier K. Attrition in randomized clinical trials: methodological issues in psychopharmacology. Biol Psychiatry. 2006;59(11):1001-5.
35. Gueorguieva R, Krystal JH. Move over ANOVA: progress in analyzing repeated-measures data and its reflection in papers published in the Archives of General Psychiatry. Arch Gen Psychiatry. 2004;61:310-7.